https://www.selleckchem.com/
2% of patients after 6 months of treatment (P less then 0.0001). The mean MMS increased from 68.8 to 83.1 (P less then 0.0001). A decrease in steroid dosage ( less then 10 mg/day) was effective in 57.9% of treated patients. In all, 42.8% of patients experienced adverse events infections (21.4% of patients); infusion reaction (7%); bradycardia (3.7%); and cytopenia (7%). Conclusion The present study demonstrates the efficacy and safety of rituximab in patients with MG. Additional studies remain necessary to determine the role of rituximab in the pharmacopeia
Like
Comment
Share
